Literature DB >> 11028718

Thymic carcinoma--analysis of nineteen clinicopathological studies.

D A Chung1.   

Abstract

BACKGROUND: Primary thymic carcinomas are rare tumours with nonuniform management protocols and poor prognosis due to delayed diagnosis and highly malignant behaviour. This review summarises the major clinicopathological studies to assess more fully the prognostic importance of tumour histology and staging as well as treatment benefit.
METHODS: A Medline search from 1966 to date was carried out and relevant references gleaned from these. Nineteen clinicopathological studies form the core of this review. Demographic data and clinical features were examined in all studies. Correlation of outcome with histology was possible in fifteen of the studies and with tumour staging in thirteen.
RESULTS: Thymic carcinomas occur most commonly in the fifth to sixth decades of life, usually presenting with symptoms of space occupation or invasion. Paraneoplastic syndromes are rarely associated, except with the well differentiated thymic carcinoma. Of 140 thymic carcinomas, 40 were squamous cell, 19 were spindle cell and 16 were lymphoepithelioma-like. Completely resected stage I and II tumours demonstrated the best survival.
CONCLUSIONS: Complete surgical resection is taken to be the desired treatment, but the continued high mortality and relapse rates and the variable benefit of adjuvant therapies challenge this strategy.

Entities:  

Mesh:

Year:  2000        PMID: 11028718     DOI: 10.1055/s-2000-9868

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  14 in total

1.  Prognostic factors of patients with thymic carcinoma after surgery: a retrospective analysis of 58 cases.

Authors:  Shuai Wang; Zhou Wang; Xiangyan Liu; Dong Wang; Fanying Liu
Journal:  World J Surg       Date:  2014-08       Impact factor: 3.352

Review 2.  Video-assisted and minimally-invasive open chest surgery for the treatment of mediastinal tumors and masses.

Authors:  George Rakovich; Jean Deslauriers
Journal:  J Vis Surg       Date:  2017-03-08

3.  Epithelial thymic tumours in paediatric age: a report from the TREP project.

Authors:  Elena Carretto; Alessandro Inserra; Andrea Ferrari; Massimo Conte; Andrea Di Cataldo; Roberta Migliorati; Giovanni Cecchetto; Gianni Bisogno
Journal:  Orphanet J Rare Dis       Date:  2011-05-21       Impact factor: 4.123

4.  Thymic carcinoma initially presented with geographic destruction of scapula in a child.

Authors:  Won-Jong Bahk; An-Hi Lee; Eun-Deok Chang; Dong-Wook Min; Yong-Koo Kang
Journal:  Skeletal Radiol       Date:  2017-06-23       Impact factor: 2.199

5.  Thymic carcinoma with combined resection of the hemisternum.

Authors:  Ryo Maeda; Noritaka Isowa; Hideyuki Onuma; Hiroshi Miura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-07-08

6.  Thymic carcinoma with brain metastasis mimicking meningioma.

Authors:  Jung Yong Ahn; Nam Keun Kim; Doyeun Oh; Hui Jung Ahn
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

7.  Clinical and immunohistochemical study of eight cases with thymic carcinoma.

Authors:  Masaki Tomita; Yasunori Matsuzaki; Masao Edagawa; Masayuki Maeda; Tetsuya Shimizu; Masaki Hara; Toshio Onitsuka
Journal:  BMC Surg       Date:  2002-05-23       Impact factor: 2.102

8.  Chronic shoulder pain referred from thymic carcinoma: a case report and review of literature.

Authors:  Shu-Wei Dee; Mu-Jung Kao; Chang-Zern Hong; Li-Wei Chou; Henry L Lew
Journal:  Neuropsychiatr Dis Treat       Date:  2012-09-04       Impact factor: 2.570

Review 9.  Chemotherapy for thymic carcinoma and advanced thymoma in adults.

Authors:  Mao Ling Wei; Deying Kang; Lijia Gu; Meng Qiu; Liao Zhengyin; Yanming Mu
Journal:  Cochrane Database Syst Rev       Date:  2013-08-23

10.  Brain metastasis from invasive thymoma mimicking intracerebral hemorrhage: case report.

Authors:  Shinya Haryu; Atsushi Saito; Mizuho Inoue; Seiya Sannohe; Hidekachi Kurotaki; Hiroyuki Kon; Tatsuya Sasaki; Michiharu Nishijima
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-12-05       Impact factor: 1.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.